Test Price
700 AED✅ Home Collection Available
Sickle Cell Disease Mutation Screening in Dubai | HbS Genetic Carrier & Diagnosis Test
Executive Summary & Core Metrics
Executive Summary: The Sickle Cell Disease Mutation Screening delivers 99.9% diagnostic sensitivity through ISO-accredited endpoint PCR methodology. This molecular genetic test identifies point mutations in the HBB gene, definitively confirming carrier status or sickle cell disease before clinical symptoms manifest. Results are available within 3–4 days, enabling timely reproductive counseling and preventive care planning.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain and VIP Mobile Phlebotomy.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The Sickle Cell Disease Mutation Screening employs endpoint polymerase chain reaction (PCR) with allele-specific amplification to detect clinically significant point mutations in the beta-globin gene (HBB). This molecular approach distinguishes homozygous disease (HbSS), heterozygous carrier state (HbAS), and compound heterozygous conditions (HbSC, HbSβ-thalassemia) with definitive accuracy. A peripheral blood sample is collected, DNA is extracted, and targeted amplification identifies the precise genetic variant present. Results are correlated with complete blood count and hemoglobin electrophoresis for comprehensive clinical interpretation.
| Parameter | Our Test (Endpoint PCR) | Sickling Solubility Test |
|---|---|---|
| Precision | Detects specific mutations (HbS, HbC, HbE, HbSβ-thal) | Only indicates presence of HbS; high false positives |
| Method | Endpoint PCR + Allele-Specific Amplification | Sodium metabisulfite sickle cell slide test |
| Turnaround Time | 3–4 Days | Same Day |
| Clinical Value | Definitive carrier/disease status, prenatal & premarital screening | Presumptive only; cannot distinguish trait vs. disease |
Physician Insight & Safety Protocols
“A positive mutation screen for sickle cell disease is never a standalone diagnosis—it must be correlated with hemoglobin electrophoresis, complete blood count indices, and a detailed family pedigree. Early molecular detection through endpoint PCR empowers at-risk couples to make informed reproductive decisions and access preconception counseling, folic acid prophylaxis, and coordinated hematology care well before symptoms emerge.” — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory: Medication & Clinical Guidance
⚠️ Important Clinical Notice
Do not discontinue any prescribed medication, including hydroxyurea or chronic transfusion regimens, without consulting your treating hematologist. This molecular screening test is designed for genetic risk assessment and does not replace a comprehensive medical evaluation, including physical examination and laboratory monitoring.
Test results should be interpreted by a qualified medical geneticist or hematologist in the context of the patient's full clinical picture.
Exclusion Criteria & Emergency Red Flags
Safety Exclusion Criteria & Red Flags
- Do not draw blood if: patient has acute febrile illness, severe anemia (Hb <7 g/dL), or is hemodynamically unstable.
- Postpone testing: for 3 months after blood transfusion to avoid donor DNA interference.
- ER Red Flags: If patient experiences sudden severe bone pain, fever >38.5°C, acute dyspnea, splenic sequestration (left upper quadrant mass + hypotension), seek emergency care immediately.
Patient FAQ & Clinical Guidance
1. How is the Sickle Cell Disease Mutation Screening performed?
A peripheral blood sample is collected by a trained phlebotomist, genomic DNA is extracted from white blood cells, and endpoint polymerase chain reaction with allele-specific primers targets the HBB gene's clinically relevant point mutations (HbS, HbC, HbE, and common β-thalassemia variants). The assay detects heterozygous carrier, homozygous disease, and compound heterozygous states with 99.9% diagnostic sensitivity. Results are typically reported within 3–4 business days.
2. Can this test be performed on children under 18 years of age?
Yes, the test may be performed on minors with written informed consent from a parent or legal guardian, in accordance with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields and pediatric ethical guidelines established by the Dubai Health Authority. Molecular screening for sickle cell disease is particularly valuable for early identification of at-risk infants before clinical complications arise.
3. Is a doctor’s prescription required for this genetic test in the UAE?
A physician's referral is mandatory for routine diagnostic sickle cell mutation screening. However, a prescription is not required when the test is ordered as part of premarital screening programs mandated by UAE federal law, prenatal genetic assessment, or pre-operative evaluation. Patients are encouraged to consult with their primary care provider or a genetic counselor to determine the most appropriate testing pathway for their individual circumstances.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Protection Framework
- All genetic data is processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), ensuring strict confidentiality and lawful handling of sensitive health information.
- Health information systems and clinical data exchange adhere to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, guaranteeing secure digital infrastructure for test ordering, result delivery, and telephonic guidance.
- Patient safety and informed consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring all clinical procedures meet the highest standard of care.
- ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | Sickle Cell Disease Mutation Screening (HBB Gene by Endpoint PCR) |
| Price (AED) | 700 AED |
| Turnaround Time | 3–4 Business Days |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA Tube) |
| Methodology Used | Endpoint PCR with Allele-Specific Amplification |
| ICD-10-CM Code | Z13.0 (Screening for genetic and chromosomal anomalies), D57.3 (Sickle-cell trait) |
| LOINC Code | 29697-3 (HBB gene mutation analysis in Blood by Molecular genetics method) |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians